Jun 30, 2021

Interpublic Group Q2 2021 Earnings Report

Interpublic Group's Q2 2021 earnings showcased resilience and a remarkable rebound, marking the largest second quarter in the company's history.

Key Takeaways

Interpublic Group reported strong Q2 2021 results, demonstrating resilience and a remarkable rebound from the pandemic's impact. The company's net organic revenue growth was 19.8%, with double-digit growth rates around the world. The adjusted EBITA margin on net revenue was 17.9%.

Net organic revenue growth in the second quarter was 19.8%.

Adjusted EBITA was $405.8 million and adjusted EBITA margin on net revenue was 17.9%.

Diluted earnings per share was $0.66 as reported and $0.70 as adjusted.

The company upgraded its full-year organic growth outlook to 9% to 10% and adjusted EBITA margin to approximately 16.0%.

Total Revenue
$2.27B
Previous year: $2.03B
+12.0%
EPS
$0.7
Previous year: $0.23
+204.3%
Organic Revenue Growth
19.8%
Previous year: -9.9%
-300.0%
Adjusted EBITA Margin
17.9%
Previous year: 3.4%
+426.5%
Gross Profit
$484M
Previous year: $230M
+110.0%
Cash and Equivalents
$2.34B
Previous year: $1.09B
+114.7%
Free Cash Flow
$434M
Previous year: -$114M
-479.7%
Total Assets
$17.3B
Previous year: $4B
+333.0%

Interpublic Group

Interpublic Group

Forward Guidance

The company expects to deliver organic growth for the full year of 9% to 10%, and achieve 2021 adjusted EBITA margin of approximately 16.0%.

Positive Outlook

  • Continued progress on public health issues.
  • Reasonably steady course of macro recovery.
  • People continue to become vaccinated to protect themselves and their communities.
  • The company is able to adequately mitigate the impact of dangerous new variants.
  • The company is well-positioned to enhance value for all of its stakeholders.

Challenges Ahead

  • COVID pandemic and the related risks to the macro environment are not yet behind us.
  • Lagging vaccination rates in many parts of the world.
  • Emergence of new variants may entail higher COVID risks.
  • Potential deterioration on the public health front.
  • Increase in travel costs in the fourth quarter, which could return to levels consistent with what we saw in the fourth quarter of 2019.